Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 883 / https://doi.org/10.3332/ecancer.2018.883

Review

Targeted literature review of the global burden of gastric cancer

Gastric cancer (GC) and gastroesophageal junction cancers (GEJCs) are the third leading cause of cancer-related death worldwide. Although several studies have evaluated the epidemiology and management of GC and GEJC, to our knowledge, no global estimates of the economic burden of GC and GEJC have yet been reported. This targeted literature review was conducted to summarise the epidemiology and management of GC and GEJC and to estimate its global economic and humanistic burden.

The incidence of GC and GEJC is highest in Eastern Asia, several South and Central American countries and Central and Eastern Europe and lowest in North America and Africa. Prognosis is generally poor; the global 5-year survival rate is 5%–10% in advanced stages. Patients with GC and GEJC have more severe symptoms compared with patients with other cancers, and health-related quality of life (HRQoL) worsens as the disease progresses. Given the rapid progression of GC and GEJC at advanced stages, chemotherapy, despite its toxicity, improves HRQoL compared with best supportive care.

The costs of GC/GEJC are generally higher than for other cancers; in the US, the average annual cost per patient between 1998 and 2003 was 46,501 USD, compared with 29,609 USD and 35,672 USD for colorectal and lung cancer, respectively. Based on the 2012 incidence data and average costs per patient, estimates of the annual financial burden of GC and GEJC revealed great regional differences. Japan and Iran had the highest (8,492 million USD) and lowest (27 million USD) costs for 2017, respectively, while the estimate for the US was 3,171 million USD. The overall annual cost of GC and GEJC estimated for 2017 in a geographic area including Europe (France, Germany, Italy, Spain and the UK), Asia (Iran, Japan and China), North America (Canada and the US) and Australia was 20.6 billion USD.

Keywords: gastric cancer, gastroesophageal junction, humanistic, economic, burden, global

Loading Article Metrics ... Please wait

Related articles

Research: ReDO_DB: the repurposing drugs in oncology database

Abstract | Full Article | PDF Published: 06 Dec 2018 / https://doi.org/10.3332/ecancer.2018.886

Review: Fertility preservation in ovarian tumours

Abstract | Full Article | PDF Published: 06 Dec 2018 / https://doi.org/10.3332/ecancer.2018.885

Research: Detection of precancerous lesions in the cervix and HPV infection in women in the region of Maniapure, Bolivar State

Abstract | Full Article | PDF | Spanish Published: 03 Dec 2018 / https://doi.org/10.3332/ecancer.2018.884

Case Report: Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation

Abstract | Full Article | PDF | Spanish Published: 20 Nov 2018 / https://doi.org/10.3332/ecancer.2018.882

Short Communication: Learning from the past to design better trials in second-line treatment for mesothelioma patients

Abstract | Full Article | PDF Published: 08 Nov 2018 / https://doi.org/10.3332/ecancer.2018.881



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation